: JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics

Additionally, those practicing intermittent fasting experienced improved insulin sensitivity, further supporting blood sugar stability and weight management
doi: 10.1080/00365521.2022.2041084
Monitor Your Blood Pressure If you have a home blood pressure monitor, checking your levels once or twice a week can provide valuable data for your doctor
How to make it: Toast one slice of sprouted grain bread Mash of a ripe avocado on top Sprinkle with salt, pepper, and (if you like) a pinch of crushed red pepper or lemon juice Serve with a side of cucumber slices or cherry tomatoes for added fiber and hydration
In T2DM, there is reduced prandial release of GLP-1 with preserved pancreatic response , making GLP-1 an attractive pathway for antihyperglycaemic agents